With regards to ongoing communication in the media and Gusten Danielsson’s statement in Dagens Industri prompted by the fact that he recently chose to resign from his position, the Board of Directors has chosen to address the issue. Both the Board of Directors and management have intended to handle the situation professionally.

There has been speculation in the media about the incident and the former employee has also quickly expressed opinions about the CEO and the leadership of the company. The Board of Directors would like to point out that the company has been careful to follow both stock exchange rules and labor laws in its communication to the market, as the company’s former CFO is still employment obligations until the notice period of six months ends.

“It is obvious that in recent times there have been divided opinions about the strategic direction. Our focus is now on profitability and building of a financially sustainable business backed by an experienced and strong finance department. We are now focused on recruiting an experienced and robust CFO who can assist the company in achieving the goals that the market and shareholders expect and that the company has previously communicated” says Carsten Browall, Chairman of the Board of Directors, BICO.

“Due to speculations, we on the Board of Directors want to make it clear that we are fully united behind the CEO, the management team and the strategy with focus on profitability. The company has great potential and is now entering an important stage for the future,” says Carsten Browall, Chairman of the Board of Directors, BICO

For further information, please contact:

Carsten Browall, Chairman of the Board of Directors, BICO

Phone (EU): +46 702556532

Email: cbr@bico.com

Avijit Minocha, Head of Marketing, BICO

Phone (US): +1 (617) 637 5372
Email: akm@bico.com

This information was submitted for publication, through the agency of the contact persons set out above, on April, 27, 2022 at 18:10 (CEST).

About BICO

Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people's health and lives for the better.

The company has a focus on developing technologies that will advance Health 4.0 Next Generation Core Industry Ecosystems that enable tissue engineering, diagnostics, multiomics, and cell line development. BICO’s technologies enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health.  

The Group’s instruments in the field amounts to 25,000, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,500 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com

Contact us!

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.